Carrie McAdam-Marx, M.S.C.I., Ph.D., R.Ph. is Professor and Director of the Social and Administrative Pharmacy... Read Bio
The goal of this study is to help decision makers better understand insulin price sensitivity following out-of-pocket (OOP) increases, and the consequences of cost-related non-adherence. With the dramatic increase in the price of insulin in recent years, patients have experienced a substantial increase in their OOP costs. Approximately 30% of patients require insulin to manage their disease, but prior research identified that patients’ OOP cost for insulin increased 150% between 2000 and 2010, thus becoming unaffordable for many patients. Using OptumLabs data from 2007 – 2018, the researchers will conduct a retrospective cohort study to examine the association between increases in insulin OOP cost and the use of insulin and non-insulin diabetes medications, as well as the association with other diabetes-related outcomes (e.g. poor blood sugar control, emergency department (ED) visits and hospitalizations). Deliverables will include a project work plan and final narrative report. The researchers will also produce paper(s) suitable for publication and present findings at national research meetings and to other stakeholder audiences as appropriate, including policymakers at the federal, state, and local levels and other key stakeholders, as part of the deliverables for this grant.
Grantee Institution: University of Nebraska Medical Center
Grant Period: 1/1/20 – 12/31/20